Intra-arterial Hypothermic Magnesium Sulfate Infusion in Combination with Endovascular Thrombectomy in Acute Ischemic Stroke

NCT ID: NCT06760195

Last Updated: 2025-01-07

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: EARLY_PHASE1
• Total Enrollment: 6 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-01-10
• Study Completion Date: 2025-06-30

Brief Summary

The primary objective of this study is to estimate the safety of intra-arterial hypothermic magnesium sulfate infusion after endovascular thrombectomy in patients with acute ischemic stroke

Conditions

Acute Ischemic Stroke

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Intra-arterial hypothermic magnesium sulfate infusion

Patients will receive intra-arterial hypothermic magnesium sulfate infusion after endovascular thrombectomy.

Group Type: EXPERIMENTAL

Intra-arterial hypothermic magnesium sulfate infusion

Intervention Type: PROCEDURE

According to patient's weight, magnesium sulfate (MgSO4) will be diluted to 330 ml 4°C saline solution (0.6μmol/kg/ml). During the thrombectomy procedure, a micro-catheter will be advanced until it reaches beyond the clot responsible for the ischemic symptoms, then cold 30 ml MgSO4 solution will be infused into the ischemic territory at 15 ml/min through the micro-catheter. After that, thrombectomy with a stent retriever will be performed to recanalize the occluded vessel as soon as possible. Immediately after successful thrombectomy, cold MgSO4 solution will be re-infused into the ischemic brain tissue through the catheter at a rate of 30 ml/min for 10 min.

Endovascular thrombectomy

Intervention Type: PROCEDURE

All patients that are eligible for endovascular thrombectomy will receive this surgery in aim to remove thrombus and restore reperfusion.

Intravenous thrombolysis

Intervention Type: DRUG

All patients that are eligible for Intravenous thrombolysis will receive 0.9mg/kg rt-PA in aim to remove thrombus and restore reperfusion

Interventions

Intra-arterial hypothermic magnesium sulfate infusion

According to patient's weight, magnesium sulfate (MgSO4) will be diluted to 330 ml 4°C saline solution (0.6μmol/kg/ml). During the thrombectomy procedure, a micro-catheter will be advanced until it reaches beyond the clot responsible for the ischemic symptoms, then cold 30 ml MgSO4 solution will be infused into the ischemic territory at 15 ml/min through the micro-catheter. After that, thrombectomy with a stent retriever will be performed to recanalize the occluded vessel as soon as possible. Immediately after successful thrombectomy, cold MgSO4 solution will be re-infused into the ischemic brain tissue through the catheter at a rate of 30 ml/min for 10 min.

Intervention Type: PROCEDURE

Endovascular thrombectomy

All patients that are eligible for endovascular thrombectomy will receive this surgery in aim to remove thrombus and restore reperfusion.

Intervention Type: PROCEDURE

Intravenous thrombolysis

All patients that are eligible for Intravenous thrombolysis will receive 0.9mg/kg rt-PA in aim to remove thrombus and restore reperfusion

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Age range of 18-80 years old (including critical value);

2. No gender restrictions;

3. The clinical diagnosis is acute ischemic stroke of the anterior circulation, and the site of acute occlusion of the responsible vessel is located in the intracranial segment of the internal carotid artery and the M1 or M2 segment of the middle cerebral artery;

4. The symptoms and signs are consistent with acute anterior circulation ischemic stroke, NIHSS≥6;

5. The time from onset to endovascular thrombectomy of acute ischemic stroke is within 24 hours;

6. Indications for endovascular thrombectomy of acute ischemic stroke: ① ASPECTS score ≥ 6 points, within 6 hours of onset; ② 6-16 hours after onset, meeting DEFUSE-3 criteria (infarct core volume < 70 mL, mismatch rate ≥ 1.8 and mismatch volume > 15 mL) or DAWN criteria (NIHSS ≥ 10 and infarct core volume < 31 mL); Or NIHSS ≥ 20 and infarct volume 31-51 mL); ③ Within 16-24 hours of onset, meet DAWN criteria (NIHSS ≥ 10 points and infarct core volume < 31mL); Or NIHSS ≥ 20 points and infarct volume 31-51 mL)

7. The mRS score before stroke is 0-1 points;

8. Written informed consent provided by the patients or their legal relatives.

Exclusion Criteria

1. Clinical manifestations suggest the presence of intracranial cerebral parenchymal hemorrhage or subarachnoid hemorrhage (even if imaging results are normal);

2. During a stroke, accompanied by epilepsy, an accurate NIHSS score cannot be obtained;

3. Accompanied by coma or mental disorders, it may interfere with the assessment of neurological function;

4. History of allergy to iodinated contrast agents or history of anaphylactic shock;

5. Baseline blood glucose<50mg/dL (2.78mmol) or>400mg/dL (22.20mmol);

*Acceptable fingertip blood glucose results

6. Baseline platelet count<50 × 10^9/L;

7. Recently (i.e. within 30 days prior to inclusion in the study), there has been a history of significant gastrointestinal or other clinically significant bleeding; Active bleeding, abnormal coagulation factors, or bleeding tendency (taking anticoagulant drugs with INR ≥ 3 or PT ≥ 3 × ULN; if the researcher believes that the subject has no coagulation dysfunction, there is no need to wait for coagulation test results to determine whether to enroll);

8. During a stroke, there may be fever or active infections that require systemic treatment (such as active pulmonary tuberculosis);

9. History of chronic heart failure with NYHA criteria>1; Uncontrolled hypertension (systolic blood pressure>180mmHg or diastolic blood pressure>105mmHg after standardized treatment), hypotension (systolic blood pressure ≤ 100mmHg after standardized treatment), unstable angina, myocardial infarction, or bypass or stent surgery within 6 months;

10. Accompanied by pulmonary diseases such as chronic obstructive pulmonary disease, tuberculosis, pneumonia, pneumothorax, atelectasis, pulmonary fibrosis, bronchopulmonary dysplasia, pleural effusion, acute respiratory distress syndrome, irregular breathing, etc;

11. Severe liver and kidney dysfunction, including but not limited to: cirrhosis, hepatic encephalopathy, ascites, renal failure or uremia (Ccr<25ml/min), hepatorenal syndrome, etc;

12. Pregnant or lactating women;

13. Patients with acute stroke within 48 hours after percutaneous cardiovascular and cerebrovascular intervention and major surgery;

14. Currently participating in interventional clinical trials and using research drugs or medical devices;

15. Participants may not be able to complete this study due to other reasons or may not be considered eligible for inclusion by the researchers;

1. CTA/MRA/DSA shows excessive vessel curvature, which may hinder the delivery of interventional instruments;

2. Suspected cerebral vasculitis based on medical history and CTA/MRA/DSA;

3. Suspected aortic dissection based on medical history and CTA/MRA/DSA;

4. CTA/MRA/DSA confirmed multi vessel regional occlusion (such as bilateral anterior circulation or anterior/posterior circulation, extracranial carotid artery with intracranial tandem lesions), or clinical evidence of bilateral infarction or multi regional infarction;

5. CTA/MRA/DSA confirms moyamoya disease or moyamoya syndrome;

6. CT/MRI confirms significant effect of midline shift;

7. CT/MRI confirms the presence of intracranial tumors (excluding small meningiomas);

8. CT/MRI confirms the presence of intracranial hemorrhage.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Capital Medical University

OTHER

Sponsor Role: lead

Responsible Party

Ji Xunming,MD,PhD

Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Xuanwu Hospital, Capital Medical University

Beijing, Beijing Municipality, China

Countries

China

Central Contacts

Xunming Ji, MD, PhD

Role: CONTACT

jixm@ccmu.edu.cn

010-83198952

Facility Contacts

Yang Zhang, MD

Role: primary

zy1192268729@163.com

010-83911991

Other Identifiers

Hypo-Mag

Identifier Type: -

Identifier Source: org_study_id